Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice

被引：19

作者：

Bethel, M. Angelyn ^{[1
,2
]}

Sourij, Harald ^{[1
,3
]}

机构：

[1] Univ Oxford, Churchill Hosp, Diabet Trials Unit, Headington OX3 7LJ, England

[2] Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27710 USA

[3] Med Univ Graz, Div Endocrinol & Metab, Graz, Austria

来源：

CURRENT CARDIOLOGY REPORTS | 2012年 / 14卷 / 01期

关键词：

Type; 2; diabetes; Cardiovascular outcome; Outcome trials; FDA guidance; Diabetes drugs;

D O I：

10.1007/s11886-011-0229-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In 2008, the US Food and Drug Administration (FDA) issued guidance requiring robust assessment of cardiovascular safety for all antidiabetic drugs to be licensed in the future. Here, we review the circumstances giving rise to the FDA guidance and describe the characteristics of clinical trials registered on ClinicalTrials.gov in the 36 months before and after the guidance was issued. We noted a doubling in the number of cardiovascular outcome trials registered and a sixfold increase in the median number of patients included in cardiovascular outcome trials in the latter 36 months. As the size and duration of follow-up for these trials increases, the clinical trials industry will need to adapt. The present review summarizes current attempts to streamline trial design and management to meet the requirements efficiently while adhering to the highest scientific standards.

引用

页码：59 / 69

页数：11

共 30 条

[1] Industry-sponsored clinical research - A broken system [J].

Angell, Marcia .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (09) :1069-1071

[2]

Barriaux Marianne, 2007, GUARDIAN

[3] Determining the most appropriate components for a composite clinical trial outcome [J].

Bethel, M. Angelyn ;

Holman, Rury ;

Haffner, Steven M. ;

Califf, Robert M. ;

Huntsman-Labed, Alice ;

Hua, Tsushung A. ;

McMurray, John .

AMERICAN HEART JOURNAL, 2008, 156 (04) :633-640

[4]

Bethel MA, 2009, DIABETES, V58, pA555

[5]

Bethel MA, 2011, DIABETIC MED, V28, pP133

[6] Clinical trial registration: a statement from the International Committee of Medical journal Editors [J].

De Angelis, C ;

Drazen, JM ;

Frizelle, FA ;

Haug, C ;

Hoey, J ;

Horton, R ;

Kotzin, S ;

Laine, C ;

Marusic, A ;

Overbeke, AJPM ;

Schroeder, TV ;

Sox, HC ;

Van der Weyden, MB .

LANCET, 2004, 364 (9438) :911-912

[7] The importance of independent academic statistical analysis [J].

Deangelis, Catherine D. ;

Fontanarosa, Phil B. .

BIOSTATISTICS, 2010, 11 (03) :383-384

[8] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[9]

Food and Drug Administration HHS, 2010, Fed Regist, V75, P59935

[10]

Graham DJ, 2003, AM J GASTROENTEROL, V98, P175

← 1 2 3 →